Trials / Terminated
TerminatedNCT02690350
An Open Study Assessing the Safety and Tolerability of U3-1784
A Phase 1, Open-label, Two-part, Safety and Tolerability Study of U3-1784 in Patients With Advanced Solid Tumours
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Daiichi Sankyo · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main objectives of the trial are: * To evaluate the safety and tolerability of U3-1784 in patients with advanced solid tumours * To determine the maximum tolerated dose (MTD) and or establish the safety and tolerability of the maximum administered dose (MAD) of U3-1784
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | U3-1784 | Solution for solution in 5% dextrose for infusion, intravenously administered every 2 weeks (q2w) as a 250 mL IV, along with colestyramine or equivalent if clinically indicated |
Timeline
- Start date
- 2016-02-29
- Primary completion
- 2017-02-28
- Completion
- 2017-02-28
- First posted
- 2016-02-24
- Last updated
- 2018-05-16
Locations
4 sites across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT02690350. Inclusion in this directory is not an endorsement.